The absorbable hemostats market has seen considerable growth due to a variety of factors.
• The absorbable hemostats market is forecast to increase from $23.59 billion in 2024 to $25.05 billion in 2025, at a CAGR of 6.2%.
Growth is fueled by advances in surgical techniques, the rising prevalence of chronic diseases, increased demand for minimally invasive surgeries, improvements in hemostatic materials, and growing patient safety awareness.
The absorbable hemostats market is expected to maintain its strong growth trajectory in upcoming years.
• The absorbable hemostats market is forecast to grow to $31.39 billion by 2029, at a CAGR of 5.8%.
This growth is attributed to the aging population, the emphasis on personalized medicine, rising healthcare spending, expanding healthcare infrastructure, and the increasing incidence of trauma. Trends include multifunctional hemostatic products, the integration of smart technologies, the use of bioengineered materials, collaborations, and advancements in regulatory standards.
The increasing number of surgical procedures is anticipated to drive the growth of the absorbable hemostats market. The rise in surgical operations is due to technological advancements, an aging population, and a growing demand for complex, minimally invasive surgeries. Absorbable hemostats are used in surgeries to control bleeding and promote clotting while being absorbed by the body over time. According to the British Association of Aesthetic Plastic Surgeons in March 2023, cosmetic procedures in the UK doubled in 2022, underscoring the rise in surgical activity and, consequently, the demand for absorbable hemostats.
The absorbable hemostats market covered in this report is segmented –
1) By Type: Thrombin-Based Hemostats, Oxidized Regenerated Cellulose-Based Hemostats, Gelatin-Based Hemostats, Collagen-Based Hemostats, Other Types
2) By Application: Neurosurgery, Orthopedic Surgery, General Surgery, Reconstructive Surgery, Other Applications
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Thrombin-Based Hemostats: Lyophilized Thrombin Hemostats, Liquid Thrombin-Based Hemostats
2) By Oxidized Regenerated Cellulose-Based Hemostats: Pre-Packaged Oxidized Cellulose Hemostats, Customizable Oxidized Cellulose Products
3) By Gelatin-Based Hemostats: Gelatin Sponge-Based Hemostats, Gelatin Foam-Based Hemostats
4) By Collagen-Based Hemostats: Collagen-Based Pads or Sheets, Collagen-Based Sponges or Powder
5) By Other Types: Fibrin-Based Hemostats, Polymeric-Based Hemostats, Other Innovative Or Hybrid Formulations
Leading companies in the absorbable hemostats market are focusing on advanced products like absorbable hemostatic powders to quickly control bleeding during surgeries. These powders promote rapid clot formation and are naturally absorbed by the body. In July 2023, Baxter International Inc. launched PERCLOT absorbable hemostatic powder, which forms a gel-like matrix to stop bleeding, improving the management of intraoperative bleeding and reducing the need for blood transfusions.
Major companies operating in the absorbable hemostats market are:
• Johnson & Johnson
• Medtronic Plc
• Becton
• Dickinson and Company
• Stryker Corporation
• Baxter International Inc.
• CSL Behring
• B. Braun Melsungen AG
• Teleflex Incorporated
• Samyang Holdings Corporation
• Integra LifeSciences
• Acelity
• Meril Life Sciences Pvt. Ltd.
• Gelita AG
• CryoLife Inc.
• Anika Therapeutics Inc.
• Z-Medica LLC
• Cohera Medical Inc.
• Marine Polymer Technologies Inc.
• Curasan AG
• Hemostasis LLC
• Arch Therapeutics Inc.
• Cura Medical
• Ferrosan Medical Devices A/S
• FzioMed Inc.
• Guizhou Jin Jiu Biotech Co. Ltd.
North America was the largest region in the absorbable hemostats market in 2024. The regions covered in the absorbable hemostats market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.